Scale -

  • Revenue is 33700 Rs Cr; Continuous Growth over 3 years; in Top Quartile; 5 Year CAGR is 12 %
  • Ebitda is 7812 Rs Cr; in Top Quartile; 5 Year CAGR is 16 %; Annual Decline is -19 %
  • PAT is 4144 Rs Cr; in Top Quartile; 5 Year CAGR is 18 %; Annual Decline is -27 %
  • Quarterly Revenue is 8070 Rs Cr; in Top Quartile
  • Quarterly Ebitda is 860 Rs Cr; in Top Quartile
  • PBT is 552 Rs Cr; Annual Decline is -30 %

Profitability -

  • PBDIT Margin is 23.18 %; Annual Decline is -22 %; Continuous Decline over 3 years
  • PAT Margin is 12.29 %; Annual Decline is -30 %; Continuous Decline over 3 years
  • Quarterly Ebitda Margin is 11 %; in Bottom Quartile
  • Quarterly Profit margin is 5 %; in Bottom Quartile

Return -

  • ROCE is 13.9 %; Annual Decline is -36 %; Continuous Decline over 3 years; in Bottom Quartile
  • ROA is 7.21 %; Annual Decline is -37 %; Continuous Decline over 3 years
  • ROE is 11.07 %; Annual Decline is -34 %; Continuous Decline over 3 years; in Bottom Quartile
  • Asset Turnover is 63 %; Continuous Decline over 3 years

Efficiency -

  • Operating cash flow is 5674 Rs Cr; Continuous Growth over 3 years; in Top Quartile
  • Inventory Turnover Ratio is 4.57; 5 Year CAGR is 52 %
  • Current Ratio is 1.8; Continuous Decline over 3 years
  • Quick Ratio is 1.35; Continuous Decline over 3 years

Solvancy -

  • Long term Debt is 0 Rs Cr; Annual Decline is -100 %
  • Contingent Liabilities is 1337 Rs Cr; Continuous Decline over 3 years
  • Debt/Equity is 0.17; Annual Growth is 42 %; Continuous Growth over 3 years
  • Total Debt is 6294 Rs Cr; Annual Growth is 50 %; Continuous Growth over 3 years; in Top Quartile

Quality -

  • Operating cashflow/ebitda is 73 %; Annual Growth is 51 %; in Top Quartile
  • Operating cashflow/PAT is 137 %; Annual Growth is 68 %; in Top Quartile
  • Change in Inventories/Total Expenses is -1 %; Annual Growth is 32 %; Continuous Growth over 3 years
  • Exceptional Items/PBT is 0 %; in Top Quartile

Quarterly Results- overall

Annual Results- Scale

Annual Results- Liquidity

Annual Results- Profitability/Return

Annual Results- Valuation

External Ecosystem

Sector
Major Subsidiaries/Associates
Key Clients

Products

Products
Product details

Operations

Capacity/ Production
Key Facilities
Key Certifications
Raw materials
Recent News
October 23 earnings call transcript is now available from Dr. Reddy’s (RDY).
Read More
  • Past/current
Pomerantz LLP investigates Dr. Reddy's over semaglutide-linked losses
Read More
  • Past/current
SEC Form 6-K filed by Dr. Reddy's Laboratories Ltd
Read More
  • Past/current
Stocks in Focus: Dr Reddy’s Lab, Titagarh Rail, and Others
Read More
  • Past/current
Stocks to Watch, Oct 29: TVS Motor, Fortis Healthcare, Dr Reddy’s, Bajaj Electricals, Zaggle, Awfis
Read More
  • Past/current
Technical
Read More
  • Past/current
USFDA officially closes a pre-approval plant inspection at Dr. Reddy’s (RDY).
Read More
  • Past/current
Anti-cancer drug prices slashed for 543 brands; new MRPs effective from Nov 9
Read More
  • Past/current
Dr. Reddy's Laboratories Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Read More
  • Past/current
Buzzing Stocks: Infosys down 2%, Dr Reddy’s Lab up 3% post Q2 results; Shriram Finance sheds 5%
Read More
  • Past/current
Dr Reddy's Laboratories Ltd (RDY) Shares Surge 4.1% -- What GF S
Read More
  • Past/current
Dr Reddy's Labs share price: PAT falls 36% in Q2; should you buy, sell or hold? Check targets
Read More
  • Past/current
Dr Reddy's Q2 Review: Brokerages Flag Margin Recovery As Key Growth Driver — Check Target Price, Potential Upside
Read More
  • Past/current
Dr Reddy's share price spurts 4% post Q2 earnings; analysts upgrade rating
Read More
  • Past/current
Dr. Reddy's Laboratories Ltd Stock 12-Month Price Target Raised to $14.01, Implies 6% Upside
Read More
  • Past/current
Dr. Reddy’s (RDY) submits reviews covering September 2026 quarter and half-year results.
Read More
  • Past/current
Five Stocks To Buy Today, October 27: Dr Reddy's Laboratories, Asahi India Glass, Ajanta Pharma, And More
Read More
  • Past/current
JPMorgan upgrades Dr. Reddy's after Q2 results but still remains on the sidelines; here's why
Read More
  • Past/current
Technical Analysis on One NYSE- Listed Pharmaceutical ADR – Dr. Reddy’s Laboratories Limited
Read More
  • Past/current
Dr Reddy's Laboratories Ltd (RDY) (Q2 2027) Earnings Call Highli
Read More
  • Past/current
Dr Reddy's Laboratories Ltd (RDY) (Q2 2027) Earnings Call Highlights: Margin Recovery in Focus ...
Read More
  • Past/current
Dr. Reddy's Laboratories: 3 Key Takeaways for Long-Term Investors
Read More
  • Past/current
Dr Reddy's Laboratories to announce Q1FY27 results on July 22
Read More
  • Past/current
Dr Reddy’s Q2 Results: Net profit falls as lower Lenalidomide sales hit revenue; beats estimates
Read More
  • Past/current
Dr. Reddy's Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2026
Read More
  • Past/current
Dr. Reddy's Laboratories Ltd. Estimates – NSE:DRREDDY
Read More
  • Past/current
Dr. Reddy's Laboratories Q2 Earnings Call Highlights
Read More
  • Past/current
Dr. Reddy’s Laboratories Q2 Results: ?????? **?? ??????????** ???? ??, ????? ?????????? ??????? ????
Read More
  • Past/current
Earnings call transcript: Dr. Reddy’s posts modest Q2 2026 beat, stock edges up
Read More
  • Past/current
Half Year 2027 Dr. Reddy's Laboratories Limited Earnings Call Transcript
Read More
  • Past/current
Four Stocks To Buy Today, October 22: Mphasis, Bharat Dynamics, Dr Reddy's Laboratories, Indian Hotels
Read More
  • Past/current
Dr Reddy's Gets CDSCO Panel Nod for Denosumab 120 mg/1 mL Pre-Filled Syringe
Read More
  • Past/current
Nifty Set For Higher Start; Dr Reddys Lab in Focus
Read More
  • Past/current
Top 3 stocks to buy: Bajaj Finance, Dr Reddy's Lab, Grasim Industries by Sumeet Bagadia | Target price, stop-loss
Read More
  • Past/current
Dr Reddy's Labs Gets 3 USFDA Form 483 Observations at Visakhapatnam Facility
Read More
  • Past/current
Dr Reddy's Laboratories stock in focus as USFDA completes pre-approval inspection at FTO-9 plant
Read More
  • Past/current
Dr Reddy’s Laboratories: Two major announcements to impact stock in near term
Read More
  • Past/current
India’s Food Regulator Acts Against GLP-1 Supplement for Misleading Claims
Read More
  • Past/current
Dr. Reddy’s facility in Andhra Pradesh gets 2 U.S. FDA observations
Read More
  • Past/current
Trade Idea of The Day
Read More
  • Past/current
Dr Reddy’s US arm faces $32,350 IRS penalty over fiscal year misclassification
Read More
  • Past/current